Emerging studies suggest Retatru tide , a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may provide a notable advancement for body management . Preliminary human tests have shown substantial reductions in abdominal tissue, conceivably outperforming other body composition therapies . Despite this,